UNASSIGNED: Recently, mRNA vaccines have been introduced as a safety-optimized alternative to plasmid DNA-based vaccines for protection against @entity566 . However, it remained unclear whether the short persistence of this vaccine type would limit memory responses and whether the protective immune response type would be maintained during recurrent exposure to allergen. We tested the duration of protective memory responses in @entity19 vaccinated with mRNA encoding the grass pollen allergen Phl p 5 by challenging them with recombinant allergen, 3.5, 6, and 9 months after vaccination. In a second experiment, vaccinated @entity19 were repeatedly challenged monthly with aerosolized allergen over a period of 7 months. Antibody and cytokine responses as well as @entity55 and airway hyperresponsiveness were assessed. mRNA vaccination induced robust @entity630 memory responses for at least 9 months. Vaccination efficiently suppressed @entity61 cytokines, IgE responses, and lung @entity1712 . Protection was maintained after repeated exposure to aerosolized allergen and no @entity630 associated pathology was observed. Lung function remained improved compared to nonvaccinated controls. Our data clearly indicate that mRNA vaccination against Phl p 5 induces robust, long-lived memory responses, which can be recalled by allergen exposure without side effects. mRNA vaccines fulfill the requirements for safe prophylactic vaccination without the need for booster immunizations.

Prophylactic mRNA Vaccination against Allergy Confers Long-Term Memory Responses and Persistent Protection in XXXX .

@entity1712 :: ('MESH:D004802', 'Disease') :: ['eosinophilia'] @entity55 :: ('MESH:D011014', 'Disease') :: ['lung inflammation'] @entity19 :: ('10090', 'Species') :: ['mice'] @entity566 :: ('MESH:D006967', 'Disease') :: ['allergy'] @entity61 :: ('15111(Tax:10090)', 'Gene') :: ['TH2'] @entity630 :: ('57314(Tax:10090)', 'Gene') :: ['TH1']
@entity19 :: (10090,Species) :: ['Mice']
